Dacogen comes to the rescue of MDS

by Medindia Content Team on  May 6, 2006 at 7:13 PM Drug News
RSS Email Print This Page Comment
Dacogen comes to the rescue of MDS
Myelodysplastic syndromes (MDS) is a type of disorder in which in which the bone marrow stops producing mature Red blood cells (RBC). Due to this the patients lack enough number of RBCs and resulting in improper functioning of the body. Typical symptoms include weakness, fatigue, infections, easy bruising, bleeding, and fever. Hence the Food and Drug Administration approved Dacogen injections for the treatment of MDS.

These injections promote the normal development of blood cells. The FDA has given the drug an orphan drug status. This is because it is used in the treatment of rare diseases or conditions that affect fewer than 200,000 people in the U.S. the approval
has been an alternative for people suffering from MDS as they can avoid blood transfusions says Steven Galson, MD, Director of FDA's Center for Drug Evaluation and Research. As of now there is no clear evidence for the cause of MDS. They can develop following treatment with drugs or radiation therapy for other diseases and can progress to acute myeloid leukemia (AML). Statistics show that about 7,000 to 12,000 new cases are diagnosed yearly in the US.

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
Notify me when reply is posted
I agree to the terms and conditions
guest Tuesday, June 27, 2006

Where can we get Dacogen? Thank you

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive